Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Investor Presentation (September 2021)
15 slides from Aquestive Therapeutics's investor presentation, Sep 13, 2021
Slide 1: Aquestive Therapeutics Corporate Presentation
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. September 2021 Aquestive Therapeutics Corporate Presentation
Slide 2: Forward-Looking Statement
Advancing medicines. Solving problems. Improving lives. Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “w
Slide 3: Our Path
Advancing medicines. Solving problems. Improving lives. Our Path Proven track record of success • Technology-based pharmaceutical company • 5 FDA-approved products • 10+ years of product sales • 200+ patents worldwide 3 Near-term pipeline catalysts • Libervant™ Buccal Film (Diazepam) ‒ NDA filed on
Slide 4: PharmFilm Technology – Where You Need It, When You Need It
Advancing medicines. Solving problems. Improving lives. PharmFilm® Technology – Where You Need It, When You Need It™ 4
Slide 5: Our Team
Advancing medicines. Solving problems. Improving lives. Our Team Keith J. Kendall Chief Executive Officer and Director Daniel Barber Chief Operating Officer Peter Boyd SVP, Business Process & Information Technology Lori J. Braender General Counsel and Chief Compliance Officer Ken Marshall Chief Comm
Slide 6: Our Products
Advancing medicines. Solving problems. Improving lives. Our Products AQST-108-SF (Epinephrine) (Alternate Indications) FDA Approved 2018 SYMPAZAN® Oral Film (Clobazam) (Lennox-Gastaut syndrome) AQST-305-SF (Octreotide) (Acromegaly/Carcinoid Syndrome) AQST-109-SF (Epinephrine) (Anaphylaxis) Proprieta
Slide 7: Solving problems in epilepsy
Advancing medicines. Solving problems. Improving lives. • Commercialized for Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy characterized by multiple manifestations of cognitive impairment and developmental delays1. Solving problems in EPILEPSY: 7 ≈700K prescriptions annually have se
Slide 8: Continued Expansion of Epilepsy Franchise
Advancing medicines. Solving problems. Improving lives. Continued Expansion of Epilepsy Franchise SYMPAZAN: Sustained Script Growth for Over 10 Quarters • Growing prescriber base, with over 30% penetration into the focused group of prescribers, with ~80% writing multiple scripts • Launched as a prec
Slide 9: Libervant: NDA Resubmission
Advancing medicines. Solving problems. Improving lives. LIBERVANT: NDA Resubmission Original NDA Submission • November 2019 CRL Received • September 2020 NDA Resubmission • June 23, 2021 Expected LAUNCH • Early 2022 9 PDUFA Date • December 23, 2021
Slide 10: Solving Problems in Anaphylaxis
Advancing medicines. Solving problems. Improving lives. Solving Problems in ANAPHYLAXIS • Anaphylaxis is an unpredictable, severe systemic allergic reaction that is rapid in onset and potentially fatal7 • At-risk patients should always have immediate access to 2 doses of epinephrine8 • Delayed admin
Slide 11: Key Pipeline Milestones
Advancing medicines. Solving problems. Improving lives. Key Pipeline Milestones 2021 2022 1H 2H 1H 11 AQST-108-SF (Epinephrine) Libervant™ Oral Film (Diazepam) PDUFA Date 12/23/21 NDA resubmission 6/23/21 Continued market formation and penetration AQST-109-SF (Epinephrine) Sympazan® Oral Film (Cloba
Slide 12: Financial Summary
Advancing medicines. Solving problems. Improving lives. Financial Summary 12 Capital Adequacy • Cash on hand ($34.2 million at 6/30/21) • Results from business performance, ATM activity, and expense management provide 12 months or more of capital with additional options and supports possible launch
Slide 13: Our Focus in 2021
Advancing medicines. Solving problems. Improving lives. Our Focus in 2021 Continue to expand in our epilepsy franchise • Focus on the FDA approval and launch of LIBERVANT • Generate continued growth in SYMPAZAN prescriptions Advance our novel epinephrine delivery platform • Complete and readout on c
Slide 14: References
Advancing medicines. Solving problems. Improving lives. 14 References CORPORATE INFORMATION , PHARMFILM® TECHNOLOGY, SYMPAZAN®, LIBERVANT™ AND EPINEPHRINE DATA 1. van Rijckevorsel. Treatment of Lennox-Gastaut syndrome: overview and recent findings Neuropsychiatr Dis Treat. 2008;4(6):1001-1019 2. Kwa
Slide 15: Thank You
Advancing medicines. Solving problems. Improving lives. Thank You
Aquestive Therapeutics — Investor Presentation (September 2021) on 6ix